Research project

Can new molecular imaging technology guide prostate cancer surgery?

Operation chamber
Complete removal of malignant tissue during prostate cancer surgery can be challenging, especially in later-stage disease, as it can be difficult to distinguish between cancerous and non-cancerous tissue.
Source: pixabay

The Netherlands Cancer Institute (NKI) announced that it has received funding from the Dutch Cancer Society (KWF Kankerbestrijding) to test whether a novel molecular imaging technology can guide prostate cancer surgery. The project will evaluate the imaging technology’s ability to detect prostate cancer during surgery, with the aim of performing more accurate removal of cancerous tissue.

Prostate cancer is the most common cancer among men in Europe with over 350,000 diagnosed in Europe every year. Complete removal of malignant tissue during prostate cancer surgery can be challenging, especially in later-stage disease, as it can be difficult to distinguish between cancerous and non-cancerous tissue. Accordingly, there is a crucial need for new technologies to help surgeons visualize cancer in real time during an operation to ensure that the cancer has been completely removed.

If this technique is successful, we will be able to guide the urologist in the most optimal way by combining pre-operative staging with per-operative imaging using the same tracer.

Dr Marcel Stokkel

In the joint research project, the Netherlands Cancer Institute, University of Twente and industry partners, Lightpoint Medical and Philips will evaluate a novel molecular imaging technology to image the prostate cancer biomarker Prostate Specific Membrane Antigen (PSMA) during surgery. If successful, the technology will be tested in larger clinical trials with the aim of sparing healthy tissue and reducing recurrence rates in prostate cancer surgery.

Dr Marcel Stokkel, Nuclear Medicine Physician at NKI, commented, “If this technique is successful, we will be able to guide the urologist in the most optimal way by combining pre-operative staging with per-operative imaging using the same tracer. If the resection margins can be assessed with highest accuracy during surgery, we might become able to improve recurrence and survival rates. The collaboration with Lightpoint Medical, Philips and the University of Twente is the most optimal setting to reach this goal and to complete this study.”

“We are delighted to embark on this collaboration with the NKI and Philips. Intraoperative molecular imaging holds enormous potential in prostate cancer surgery. This project will bring the technology a step closer to the patients in need of better treatment options” commented Dr David Tuch, CEO of Lightpoint Medical.


Source: Netherlands Cancer Institute

17.10.2017

Read all latest stories

Related articles

Pathology test

AI predicts prostate cancer progression following surgery

A pathology test that applies artificial intelligence (AI) to characterize tissue samples can accurately predict clinically significant prostate cancer disease progression following surgery,…

Prostate cancer

Magnetic surgery takes promising first steps

Magnets may play a central role in the future of surgery. This summer, US surgeon Dr. Jeffrey Cadeddu performed the first of several magnet-assisted prostate cancer surgeries he has now done.…

high-intensity focused ultrasound

Prostate cancer ultrasound treatment effective as others

Using high energy ultrasound beams to destroy prostate cancer tumours may be as effective as surgery or radiotherapy, but with fewer side effects. A new study, carried out at six hospitals across the…

Related products

Immunochemistry

Beckman Coulter - phi (Prostate Health Index)

Beckman Coulter, Inc.

PET-CT

Canon - Celesteion

Canon Europa NV

PET-CT

GE Healthcare - Discovery MI

GE Healthcare

Surgical II-C-arms

INTERMEDICAL - "NEW" RADIUS XP

INTERMEDICAL SRL

Surgical flat panel C-arms

INTERMEDICAL - "NEW" RADIUS XP WITH FLAT PANEL

INTERMEDICAL SRL